CN1939431B - Medicine for treating prostatic accrementition - Google Patents
Medicine for treating prostatic accrementition Download PDFInfo
- Publication number
- CN1939431B CN1939431B CN200510021789XA CN200510021789A CN1939431B CN 1939431 B CN1939431 B CN 1939431B CN 200510021789X A CN200510021789X A CN 200510021789XA CN 200510021789 A CN200510021789 A CN 200510021789A CN 1939431 B CN1939431 B CN 1939431B
- Authority
- CN
- China
- Prior art keywords
- gryllotalpa
- radix paeoniae
- paeoniae rubra
- extract
- medicine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
A Chinese medicine for treating prostatoplasia is prepared from red peony root, dung beetle and mole cricket. Its preparing process is also disclosed.
Description
Technical field
The invention belongs to the pharmaceutical technology field, exactly relating to a kind of is preparation of raw material and preparation method thereof with Radix Paeoniae Rubra, Catharsii molossi, Gryllotalpa.
Background technology
Prostatic hyperplasia (BPH) be in, the commonly encountered diseases and the frequently-occurring disease of elderly men.According to states such as America and Europe statistics, in elderly men, the prostatic hyperplasia sickness rate is up to more than 80%; Domesticly also reach more than 50%.In recent years, along with growth in the living standard, the development of Medical Technology, the average life of population also constantly prolongs, and this is the trend that rises gradually with regard to the sickness rate that has caused prostatic hyperplasia.
BPH can cause the controlled micturition difficulty, and is not to the utmost dripping, and urine urgency-frequency, nocturia increase etc., further develop to cause urine retention, and renal insufficiency, complication such as serious urinary tract infection have a strong impact on quality of life of patient.
Though operation is a treatment means the most completely, but most patients are worn with age, when treatment, must consider to block degree and whole body situation simultaneously, especially whether the heart, lung, renal function can tolerate operation, the incidence rate of operation and complication is also higher once more simultaneously, for slight hypertrophy and older and can not tolerate surgery person, Drug therapy remains the important method of at first selecting.So generally believe that now Drug therapy should be as first-line Therapeutic Method.
Modal clinically medicine is 5 inhibitor, alpha-receptor blocker and plant amedica.
The alpha-receptor blocker can improve the BPH symptom, but can not suppress the process of BPH.α 1 receptor is bigger to the influence of urinating in the alpha-receptor, and retardance α 1 receptor can reduce smooth muscle tension force, reduces urethral resistance, improves urinary function.Non-selective alpha-blocking agent has phenoxybenzamine (5～20mg is oral every night); Selectivity α 1 receptor blocking agent has alfuzosin (alfuzosin) (trade name: Sang Ta, 2.5mg, every day three times), prazosin (1mg is oral every night); Long-acting α 1 receptor blocking agent of selectivity is used terazosin (terazosin) (trade name: hytrin, homemade is Ma Shani, 2mg is oral every night), Tamsulosin (tamsulosin) (trade name: breathe out happyly, 0.2mg is oral every night) etc. always.This class medicine common adverse reactions is: postural hypotension, xerostomia, nasal obstruction, palpitating speed etc., postural hypotension often causes fractures when the old people goes to the lavatory night, is one of old people's major causes of death, so should be prudent.
Hormone medicine is the most important with the 5 inhibitor, 5 inhibitor finasteride (trade name: proscar, 5mg is oral every day) can reduce dihydrotestosterone content in the prostate, there is data proof proscar can significantly improve symptom to the half patient, approximately taking medicine to make the above prostate of 40 grams dwindle in 3 months, improved urinary function, and general greatest treatment efficacy occurred after half a year, but symptomatic recurrence after the drug withdrawal is thought at present and should be taken throughout one's life.It is poorer than the alpha-receptor blocker that it improves urinary function.Common adverse reactions is: sexual impotence, ejaculate volume minimizing, sexual hypofunction, breast increase, anaphylaxis.
The plant amedica extract: Prostat, effect relaxes, and it is effective to prostatitis to hold concurrently; Diuresis apparatus is held concurrently and can be improved the smooth muscle of bladder function; Homemade QIANLIEKANG is effective to the part patient.Its shortcoming is: effect is slow, and drug effect is relatively poor.
Summary of the invention
Purpose of the present invention just provides a kind of medicine for the treatment of prostatic hyperplasia, characteristics such as that this medicine has is rapid-action, good effect.
Another object of the present invention provides a kind of preparation method for the treatment of the medicine of prostatic hyperplasia.
The technical solution adopted for the present invention to solve the technical problems is: a kind of medicine for the treatment of prostatic hyperplasia is characterized in that being got through extracting, preparing as crude drug by Radix Paeoniae Rubra, Catharsii molossi, Gryllotalpa.
The medicine of above-mentioned treatment prostatic hyperplasia preferably is made up of the component of following weight proportion: 0.5～5 part of Radix Paeoniae Rubra, 0.5～5 part of Catharsii molossi, 0.25～2.5 part of Gryllotalpa.Further the preferred weight proportioning is: 1～3 part of Radix Paeoniae Rubra, 1～3 part of Catharsii molossi, 0.5～1.5 part of Gryllotalpa.More preferably weight proportion is: 2 parts of Radix Paeoniae Rubra, 2 parts of Catharsii molossis, 1 part of Gryllotalpa.
Wherein, described raw material should meet the medical material standard in country or each province and city, is the dry root of ranunculaceae plant Radix Paeoniae Paeonia lactiflora Pall. or river Radix Paeoniae Rubra Paeonia veitchii Lynch as Radix Paeoniae Rubra; Catharsii molossi is that this product is the dry body of Scarabaeidae insecticide dung shell dung beetle Catharsius molossus Linnaeus; Gryllotalpa is the dry body of Gryllotalpidae animal Gryllotalpa Gryllotalpa africana Palisot et Beauvois or Gryllotalpa unispina Gryllotalpa unispina Saussure.
The medicine of above-mentioned treatment prostatic hyperplasia can prepare by the method that may further comprise the steps:
(1), extract Radix Paeoniae Rubra: get the Radix Paeoniae Rubra of described proportioning, water or Different concentrations of alcohol are extracted, and the gained extracting solution is concentrated and drying, make Radix Paeoniae Rubra extract;
(2), extract Catharsii molossi, Gryllotalpa: get Gryllotalpa, the Catharsii molossi of described proportioning, extract with different concentration ethanol, reclaim ethanol, in cold preservation below 15 ℃, remove the liquid level oils and fats, will concentrate except that the medicinal liquid behind the degrease, drying gets Catharsii molossi, Gryllotalpa extract.
(3), make dosage form: get the said extracted thing, add various adjuvants according to the needs of preparation, preparation method is made various dosage forms routinely, gets final product.
When wherein extracting Radix Paeoniae Rubra in the step (1), dry again after can handling through following method earlier after the aqueous extract of gained concentrates: after the aqueous extract of gained concentrated, adding ethanol extremely wherein concentration of alcohol reaches 50%-90%, staticly settles after-filtration, gets final product concentrating behind the gained filtrate recycling ethanol.Used concentration of alcohol is 60-95% when extracting Catharsii molossi, Gryllotalpa in the step (2).
Compared with prior art, the invention has the beneficial effects as follows:
(1) compare with 5 inhibitor, alpha-receptor blocker, medicine of the present invention both can dwindle outgrowth prostate, can reduce smooth muscle tension force again, reduced urethral resistance, improved urinary function.So medicine of the present invention possesses the advantage of 5 inhibitor, alpha-receptor blocker simultaneously.
(2) compare with 5 inhibitor, alpha-receptor blocker, medicine of the present invention has no side effect under therapeutic dose, and drug safety is fit to take for a long time.
(3) compare with existing plant amedica, drug effect of the present invention is fast, and strong drug action, pharmacodynamic study show that medicine of the present invention and chemicals have the medicine with intensity.
(4) medicine of the present invention so be suitable for taking for a long time, can not produce untoward reaction because strong drug action has no side effect under the therapeutic dose.
Definite for showing curative effect of medication of the present invention, have no side effect under the therapeutic dose, the inventor has carried out pharmacodynamics test and acute toxicity test research.The research method and the result of the test that are adopted are as follows:
(1) pharmacodynamics test research
1, test material
(1), medicine and reagent:
Medicine low dose group of the present invention (dosage group in 2.1g raw medicinal herbs/kg), the medicine of the present invention (4.2g raw medicinal herbs/kg), medicine high dose group of the present invention (the 8.4g raw medicinal herbs/kg).
(trade name: the proscar sheet): every contains the 5mg finasteride to finasteride tablet, is produced lot number: 223095 by U.S. Mo Shadong pharmaceutical factory.
Terazosin (trade name: hytrin): produce, Shanghai Abbott Laboratories company limited packing, specification: 2mg/ sheet * 28 slice/box by Britain Abbott Laboratories company limited.
(2), animal: the SD rat, male, 180-240g is provided by institute of antibiotics, Sichuan Experimental Animal Center.
2, test method and result
(1) androlin is brought out the influence of castrated rats prostatic hyperplasia
Get 60 of rats, be divided into 6 groups at random, 10 every group.Rats by intraperitoneal injection pentobarbital sodium 40mg/kg anesthesia, sterilization back row excision rat bilateral testes art, 1 week of postoperative is given rat skin lower injection androlin 0.4mg/kg, the administration group is irritated stomach medicine of the present invention respectively, positive drug control group is irritated stomach finasteride (1.67mg/kg), and normal group and model group are irritated stomach distilled water 20ml/kg, 1 time/d, continuous 28d, 24h after the last administration puts to death rat, cuts open and gets prostate, weigh with torsion balance, calculate organ index (mg/100kg body weight).
Show (the X ± SD) of the outgrowth influence of rat prostate due to a pair of acetone Testosterone
Annotate: 1. model group and normal group compare △ △ △ P＜0.001
2. each administration group and matched group compare * * P＜0.01***P＜0.001
The result: the high, medium and low dosage group of medicine of the present invention all can obviously reduce the prostate index, and good than finasteride.
(2) to the influence of rat urine amount
Get 60 of rats, be divided into 6 groups at random, 10 every group.Rat is prohibited feed material 12h before the experiment, supplies water.Cause the water load to rat oral gavage tap water 20ml/kg earlier during experiment, behind the 30min, each organizes rat according to the form below filling stomach respectively, and compressing Mus lower abdomen drains surplus urine after the administration, and Mus is placed (cage is put 2 of Mus) in the metabolic cage, the urine of 5h behind the collection medicine.The result is as shown in the table.
The influence of table two pair rat urine amount (X ± SD)
Annotate: 1. model group and normal group compare △ △ △ P＜0.001
2. each administration group and matched group compare * * P＜0.01***P＜0.001
As can be seen from the above table, high, medium and low dosage group of medicine of the present invention and positive controls urine amount and normal group more all have significant difference.Show that medicine of the present invention has the good effect that improves urinary function.
(2) acute toxicity test research
The inventor has carried out the acute toxicity test investigation with mice to medicine of the present invention, the result: the maximum dosage-feeding of medicine mouse stomach of the present invention administration is 205g crude drug/kg/24h, and maximum administration multiple is intended clinical oral administration day dosage (488 times of 0.42g crude drug/kg) for 60kg body weight adult.The result shows that safety of medicine dosage range of the present invention is bigger.
The specific embodiment
The present invention is described in further detail below in conjunction with the specific embodiment.
Embodiment one to 14 is made up of the component of listed each embodiment weight proportion in the table 4 respectively.
Table three embodiment one to 14 each composition weight proportioning
The preparation method of embodiment one to three may further comprise the steps:
(1), extracts Radix Paeoniae Rubra: get the Radix Paeoniae Rubra of described proportioning, use water extraction, the gained extracting solution is concentrated and drying, make Radix Paeoniae Rubra extract;
(2), extract Catharsii molossi, Gryllotalpa: get Gryllotalpa, the Catharsii molossi of described proportioning, use 80% ethanol extraction, reclaim ethanol, in cold preservation below 4 ℃, remove the liquid level oils and fats, will concentrate except that the medicinal liquid behind the degrease, drying gets Catharsii molossi, Gryllotalpa extract.
(3), make dosage form: get the said extracted thing, add dalcium biphosphate and microcrystalline cellulose, preparation method is made tablet or capsule routinely, gets final product.
The preparation method of embodiment four to six may further comprise the steps:
(1), extract Radix Paeoniae Rubra: get the Radix Paeoniae Rubra of described proportioning, use water extraction, after aqueous extract concentrated, adding ethanol extremely wherein concentration of alcohol reached 50%-90%, staticly settles after-filtration, promptly made Radix Paeoniae Rubra extract with concentrating behind the gained filtrate recycling ethanol;
(2), extract Catharsii molossi, Gryllotalpa: get Gryllotalpa, the Catharsii molossi of described proportioning, the ethanol extraction with 60% reclaims ethanol, in cold preservation below 15 ℃, removes the liquid level oils and fats, will concentrate except that the medicinal liquid behind the degrease, and drying gets Catharsii molossi, Gryllotalpa extract.
(3), make dosage form: get the said extracted thing, add dextrin, preparation method is made granule routinely, gets final product.
The preparation method of embodiment seven to nine may further comprise the steps:
(1), extracts Radix Paeoniae Rubra: get the Radix Paeoniae Rubra of described proportioning, use 70% ethanol extraction, the gained extracting solution is concentrated and drying, make Radix Paeoniae Rubra extract;
(2), extract Catharsii molossi, Gryllotalpa: get Gryllotalpa, the Catharsii molossi of described proportioning, the ethanol extraction with 95% reclaims ethanol, in cold preservation below 10 ℃, removes the liquid level oils and fats, will concentrate except that the medicinal liquid behind the degrease, and drying gets Catharsii molossi, Gryllotalpa extract.
(3), make dosage form: get the said extracted thing, add Polyethylene Glycol, preparation method is made drop pill routinely, gets final product.
The preparation method of embodiment ten to 12 may further comprise the steps:
(1), extracts Radix Paeoniae Rubra: get the Radix Paeoniae Rubra of described proportioning, use 50% ethanol extraction, the gained extracting solution is concentrated and drying, make Radix Paeoniae Rubra extract;
(2), extract Catharsii molossi, Gryllotalpa: get Gryllotalpa, the Catharsii molossi of described proportioning, the ethanol extraction with 50% reclaims ethanol, in cold preservation below 5 ℃, removes the liquid level oils and fats, will concentrate except that the medicinal liquid behind the degrease, and drying gets Catharsii molossi, Gryllotalpa extract.
(3), make dosage form: get the said extracted thing, add the conventional adjuvant that the plant wet goods prepares soft capsule, preparation method is made soft capsule routinely, gets final product.
The preparation method of embodiment 13 to 14 may further comprise the steps:
(1), extracts Radix Paeoniae Rubra: get the Radix Paeoniae Rubra of described proportioning, use 40% ethanol extraction, the gained extracting solution is concentrated and drying, make Radix Paeoniae Rubra extract;
(2), extract Catharsii molossi, Gryllotalpa: get Gryllotalpa, the Catharsii molossi of described proportioning, the ethanol extraction with 30% reclaims ethanol, in cold preservation below 5 ℃, removes the liquid level oils and fats, will concentrate except that the medicinal liquid behind the degrease, and drying gets Catharsii molossi, Gryllotalpa extract.
(3), make dosage form: get the said extracted thing, adding starch etc. prepares the conventional adjuvant of pill, and preparation method is made pill routinely, gets final product.
Claims (5)
1. medicine for the treatment of prostatic hyperplasia is characterized in that: by following raw materials in weight portion medicine, and 0.5～5 part of Radix Paeoniae Rubra, 0.5～5 part of Catharsii molossi, 0.25～2.5 part of Gryllotalpa; Make according to following method:
(1), extract Radix Paeoniae Rubra: get the Radix Paeoniae Rubra of described proportioning, water or Different concentrations of alcohol are extracted, and the gained extracting solution is concentrated and drying, make Radix Paeoniae Rubra extract;
(2), extract Catharsii molossi, Gryllotalpa: get Gryllotalpa, the Catharsii molossi of described proportioning, extract with different concentration ethanol, reclaim ethanol, in cold preservation below 15 ℃, remove the liquid level oils and fats, will concentrate except that the medicinal liquid behind the degrease, drying gets Catharsii molossi, Gryllotalpa extract;
(3), make dosage form: get the said extracted thing, add various adjuvants according to the needs of preparation, preparation method is made various dosage forms routinely, gets final product.
2. medicine according to claim 1 is characterized in that the weight portion proportioning of each crude drug is: 1～3 part of Radix Paeoniae Rubra, 1～3 part of Catharsii molossi, 0.5～1.5 part of Gryllotalpa.
3. medicine according to claim 2 is characterized in that the weight portion proportioning of each crude drug is: 2 parts of Radix Paeoniae Rubra, 2 parts of Catharsii molossis, 1 part of Gryllotalpa.
4. medicine according to claim 1, it is characterized in that: when extracting Radix Paeoniae Rubra in the step (1), dry again after can handling through following method earlier after the aqueous extract of gained concentrates: after the aqueous extract of gained concentrated, adding ethanol extremely wherein concentration of alcohol reaches 50%-90%, staticly settle after-filtration, get final product concentrating behind the gained filtrate recycling ethanol.
5. medicine according to claim 1 is characterized in that: used concentration of alcohol is 60-95% when extracting Catharsii molossi, Gryllotalpa in the step (2).
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200510021789XA CN1939431B (en) | 2005-09-30 | 2005-09-30 | Medicine for treating prostatic accrementition |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200510021789XA CN1939431B (en) | 2005-09-30 | 2005-09-30 | Medicine for treating prostatic accrementition |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1939431A CN1939431A (en) | 2007-04-04 |
| CN1939431B true CN1939431B (en) | 2011-01-12 |
Family
ID=37958133
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN200510021789XA Expired - Fee Related CN1939431B (en) | 2005-09-30 | 2005-09-30 | Medicine for treating prostatic accrementition |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1939431B (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1522727A (en) * | 2003-03-25 | 2004-08-25 | 邵继春 | Prostate hyperplasia pharmaceutical and method for making same |
| CN1583029A (en) * | 2004-06-04 | 2005-02-23 | 成都和康药业有限责任公司 | Medicine for prostate hyperplasia and its preparation |
-
2005
- 2005-09-30 CN CN200510021789XA patent/CN1939431B/en not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1522727A (en) * | 2003-03-25 | 2004-08-25 | 邵继春 | Prostate hyperplasia pharmaceutical and method for making same |
| CN1583029A (en) * | 2004-06-04 | 2005-02-23 | 成都和康药业有限责任公司 | Medicine for prostate hyperplasia and its preparation |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1939431A (en) | 2007-04-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1762967B (en) | Enoxolone derivative, preparation method and uses | |
| CN101002912A (en) | Method for preparing Yueshu dripping pills to treat dysmenorrhea | |
| CN101612316B (en) | Application of dendrobium officinale aqueous extract in preparing medicine for preventing and treating hypertension and apoplexy | |
| CN102240318A (en) | Traditional Chinese medicine for tonifying qi and increasing breast milk | |
| CN104940479A (en) | TCM composition for treating AD diseases | |
| CN105943958A (en) | Inonotus obliquus composite solid particles for treating gout and preparing method thereof | |
| CN102526423A (en) | Medicine composition for treating ischemic heart disease | |
| CN101591374B (en) | Steroid compound, preparation method thereof, medicinal composition containing compound and application of compounds | |
| CN103356630B (en) | Containing pentoxifylline and the pharmaceutical composition of prucalopride and medical usage thereof | |
| CN103330721B (en) | Holothurian flower extract for treatment of female POF and its preparation method | |
| CN102106882A (en) | Natural compound medicine for treating acnes and scars | |
| CN1939431B (en) | Medicine for treating prostatic accrementition | |
| CN101590126B (en) | TCM composite for treating benign prostatic hyperplasia | |
| CN102138938A (en) | Composition for preparing products for improving hyperuricemia | |
| CN102258557B (en) | Medicament for treating prostatic hyperplasia | |
| CN113577090B (en) | Application of arctiin in preparation of prostatic hyperplasia medicine | |
| CN101940585A (en) | Composite using orientin-2'-O-beta-L-galactoside as main component and application thereof | |
| CN101693045B (en) | Effective portion of conical hydrangea, preparation method thereof, and composition and usage thereof | |
| CN103656161B (en) | A kind of Chinese medicine composition and its production and use | |
| CN101843851B (en) | Dendrobium officinale nimodipine combination medicine for resisting hypertension and apoplexia, and preparation method thereof | |
| CN102423384A (en) | Traditional Chinese drug preparation for treating lung cancer, and preparation method thereof | |
| CN102151275A (en) | Pancreatic cancer-resisting effect of oleanolic acid and pharmaceutical preparation of oleanolic acid | |
| CN100512827C (en) | Chinese medicine tablet of total coumarins extract from peucedanum praeruptorm and its preparing method and use | |
| CN100589800C (en) | Chinese medicine preparation of total coumarins extract from peu cedanum praeruptorum dunn, and its preparing method and use | |
| CN100574754C (en) | A kind of preparation method of total coumarins extract from peucedanum praeruptorm |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20110112 Termination date: 20130930 |